A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapy
Theranostics · 2023
DOI: 10.7150/thno.84628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2023. Verfasst von Kelly Waldeck und 7 weiteren Autor:innen. Beteiligte Einrichtung: Models of Cancer Translational Research Centre, Research Division, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, Australia, 300…. Hauptthemen laut MEDLINE: Lutetium, Neuroendocrine Tumors. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Models of Cancer Translational Research Centre, Research Division, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, Australia, 3000.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia, 3010.
- Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, Australia, 3000.
- Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia, 3010.
- Department of Clinical Pathology and University of Melbourne Centre for Cancer Research, The University of Melbourne, Parkville, Victoria, Australia, 3010.
- St Vincent's Hospital Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia, 3010.
Zitieren
APA
Waldeck, K., Van Zuylekom, J., Cullinane, C., Gulati, T., Simpson, K. J., Tothill, R. W., Blyth, B., & Hicks, R. J. (2023). A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapy. Theranostics. https://doi.org/10.7150/thno.84628
Vancouver
Waldeck K, Van Zuylekom J, Cullinane C, Gulati T, Simpson KJ, Tothill RW, et al. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapy. Theranostics. 2023. doi:10.7150/thno.84628
BibTeX
@article{Waldeck2023,
author = {Waldeck, Kelly and Van Zuylekom, Jessica and Cullinane, Carleen and Gulati, Twishi and Simpson, Kaylene J and Tothill, Richard W and Blyth, Benjamin and Hicks, Rodney J},
title = {A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapy},
journal = {Theranostics},
year = {2023},
doi = {10.7150/thno.84628}
}
EUVIMED